25 September 2024 in Veterinary Pathology
Feline eosinophilic sclerosing fibroplasia (FESF) is a proliferative, inflammatory disease of the gastrointestinal tract and other sites, uncommonly diagnosed in the cat. This entity of uncertain etiology typically presents as a progressive mass lesion, mimicking a neoplastic process. In this case series, we present 17 cases of FESF associated with intralesional lymphoma. Histologic and immunohistochemical characterization of this unique lymphoma revealed that the neoplastic lymphocytes were immunopositive for CD56 and/ or CD3, suggesting a natural killer cell, natural killer T-cell, or T-cell origin. This case series represents the first description of this lymphoma subtype, for which the term eosinophilic sclerosing lymphoma is proposed.
19 February 2025 in Veterinary Pathology
Splenic masses are common in dogs and vary dramatically in their clinical behavior. Clinically, and even with histology, it can be challenging to differentiate between benign and malignant splenic masses. Hemangiosarcoma (HSA), the most common malignancy of the spleen, is a very aggressive tumor with a poor prognosis. We hypothesize that microRNAs (miRNAs) in mass tissue and serum can differentiate between HSA and other splenic masses. Fifty-nine miRNAs were investigated by reverse-transcription followed by real-time quantitative polymerase chain reaction (RT-qPCR) in serum and/or tissue from dogs with HSAs (serum n = 24 and tissue n = 17; postsplenectomy serum n = 11), lymphomas (serum n = 8 and tissue n = 11), nonangiomatous nonlymphomatous sarcomas (serum n = 6 and tissue n = 10), histiocytic sarcomas (tissue n = 4), benign splenic masses (myelolipomas, nodular hyperplasia, and hematomas; total serum n = 21 and total tissue n = 35), and normal dogs (serum n = 14 and tissue n = 7). Numerous miRNAs were differentially expressed in serum and tissue of HSA cases compared to those with other splenic masses or normal spleens. In serum, our 5-miRNA model (miR-135a-5p, miR-10a, miR-450b, miR-152-3p, and miR-126-5p) accurately classified 100% (24/24) of dogs with HSA from normal dogs and those with a benign splenic mass (recall = 1 for HSA). The overall accuracy of the model was 86%. In HSA and benign splenic mass tissues, our 3-miRNA model (miR-126-5p, miR-502-3p, and miR-452-5p) accurately classified 96% of the cases. This study demonstrates the utility of miRNA models in serum and tissue for screening and diagnosis of HSA in dogs. Future studies include the evaluation of prospective and prediagnosis serum samples.
26 April 2021 in Tierärztliche Praxis Ausgabe K: Kleintiere / Heimtiere
Zusammenfassung: Eine 8-jährige, kastrierte Mischlingshündin wurde wegen fehlenden Harn- und Kotabsatzes vorgestellt. Bei der rektalen Untersuchung ließ sich eine glatte, kugelige, derb-elastische Masse palpieren. Die Blutuntersuchung ergab eine 6-fach erhöhte Serumaktivität der Laktatdehydrogenase. Die Befunde von Röntgen, Ultraschall und Computertomografie lieferten den Verdacht eines Leiomyoms. Ein in Sedation unter Ultraschallkontrolle entnommenes Feinnadelaspirat war nicht diagnostisch. Bei der Laparotomie konnte die Masse extraluminal am Übergang vom Colon descendens zum Rektum lokalisiert und unter Schonung des Darms in toto reseziert werden. Die histopathologischen Befunde und immunhistochemischen Färbungen bestätigten die Verdachtsdiagnose eines Leiomyoms. Die Hündin konnte postoperativ Harn und Kot absetzen und präsentierte sich nach 6 Monaten weiterhin unauffällig. Sonografisch ergab sich kein Hinweis auf ein Rezidiv und die Aktivität der Laktatdehydrogenase war nur mehr marginal erhöht.